ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

More Changes In Carcinogenesis Program At NCI: Gori, Workshops Out, Branch Chiefs Running It

November 18, 1977

Duke Insiders Allege Intimidation By Administration

July 23, 2010

O’Connor Is New NS President, Curtiss Is Next

May 24, 1991

Venter Steps Down As Celera President; Moffitt, Puerto Rico Center Win NCI P20 Grant.

January 25, 2002

In Brief: House Passes FY ’77 Money Bill, But Veto Seems Likely; NIH Relaxes Moonlighting Rule

August 20, 1976

ASCO Releases Three Guidelines For Cancer Survivorship Care

April 25, 2014